Abstract
Glucose tolerance tests in rats showed that after indomethacin treatment plasma insulin levels rose five-fold higher than in untreated controls. Accordingly, the pancreatic islets of indomethacin-treated rats secreted insulin at a threefold higher rate. Glucose tolerance tests additionally showed that indomethacin treatment led to a retarded disposal of the elevated blood glucose. Both effects appear to be caused by an attenuation of the hormone responsiveness for insulin and noradrenaline (α-adrenoceptor action) by indomethacin. The following observations support this view: insulin and adrenaline (α-adrenoceptor action) lost their ability to lower cyclic adenosine monophosphate (AMP) levels in hepatocytes; the glycogen content of liver and skeletal muscle was reduced by 95% and 65%, respectively; in adipocytes the stimulation of glucose transport by insulin was reduced by 60%. These effects of indomethacin can be reversed by the addition of exogenous prostaglandin E (PGE), as elevated cyclic AMP systhesis was again sensitive to α-adrenergic inhibition in the liver: These results indicate a relationship between prostaglandins and insulin action. These effects of indomethacin could result from reduced synthesis of cyclic PIP (prostaglandylinositol cyclic phosphate), a proposed second messenger for insulin and α-adrenoceptor action, whose synthesis was decreased by indomethacin treatment and increased by the addition of exogenous PGE. Stimulation of glucose transport by cyclic PIP was unaffected by indomethacin treatment, in contrast to the stimulation by insulin. Inhibition of PGE and cyclic PIP synthesis resulted in a metabolic state comparable to insulin resistance in non-insulin-dependent diabetes mellitus.
Similar content being viewed by others
References
Wasner HK, Leßmann M, Weber S, Prostaglandylinositol cyclic phosphate (cPIP), a second messenger for insulin. Diabetes 39 (Suppl 1):2a (abstract 8), 1990
Wasner HK, Prostaglandylinositol cyclic phosphate (cPIP), a second messenger for insulin. Acta Endocrinol 122 (Suppl 1):25 (abstract 49), 1990
Amini-Hadi-Kiashar H, Wasner HK, Prostaglandylinositol-zyklophosphat (cPIP), ein möglicher Hormonbote des Insulins, aktiviert den Glucose-Transport in isolierten Fettzellen der Ratte. Diabetes Stoffwechsel 2:107 (abstract), 1993
Vaughan M, An effect of prostaglandin E1 on glucose metabolism in rat adipose tissue. In: Bergström S, Samuelsson B (eds) Prostaglandins, Proceedings of the Second Nobel Symposium. Interscience Publishers, New York, pp 139–142, 1967
Böhle E, Rettberg H, Ditschuneit HH, Döbert R, Ditschuneit H, Tierexperimentelle Untersuchungen über die Beeinflussung des Fett- und Kohlenhydratstoffwechsels durch Prostaglandin E1. Verh Dtsch Ges Inn Med 73:797–802, 1967
Gordon RS, Cherkes A, Production of unesterified fatty acids from isolated rat adipose tissue incubated in vitro. Proc Soc Exp Biol Med 97:150–151, 1958
Steinberg D, Vaughan M, Nestel PJ, Strand O, Bergström S, Effects of the prostaglandins on hormone-induced mobilization of free fatty acids. J Clin Invest 43:1533–1540, 1964
Butcher RW, Baird CE, Effects of prostaglandins on adenosine 3′,5′-monophosphate levels in fat and other tissues. J Biol Chem 243:1713–1717, 1968
Curnow RT, Nuttall FQ, Effect of prostaglandin E1 administration on the liver glycogen synthetase and phosphorylase systems. J Biol Chem 247:1892–1898, 1972
Brass EP, Garrity MJ, Robertson RP, Inhibition of glucagonstimulated hepatic glycogenolysis by E-series prostaglandins. FEBS Lett 169:293–296, 1984
Stiegler H, Rett K, Wicklmayr M, Mehnert H, Metabolic effects of prostaglandin E1 on human skeletal muscle with special regard to the amino acid metabolism. Vasa (Suppl) 28:14–18, 1989
Wu G, Thompson IR, Arachidonic acid, prostaglandin E2 and F2α inhibit leucine degradation in chick skeletal muscle. Biochem Int 16:227–234, 1988
Turk J, Hughes JH, Easom RA, Wolf BA, Scharp DW, Lacy PE, McDaniel ML, Arachidonic acid metabolism and insulin secretion by isolated human pancreatic islets. Diabetes 37:992–996, 1988
Robertson RP, Eicosanoids as pluripotential modulators of pancreatic islet function. Diabetes 37:367–370, 1988
Vaughan M, Murad F, Adenyl cyclase in particles from fat cells. Biochemistry 8:3092–3099, 1969
Bär HP, Hechter O, Adenylyl cyclase and hormone action. I. Effects of adrenocorticotropic hormone, glucagon and epinephrine on the plasma membrane of rat fat cells. Proc Natl Acad Sci USA 63:350–356, 1969
Bronstad GO, Christoffersen T, Inhibitory effect of prostaglandins on the stimulation by glucagon and adrenaline of formation of cyclic AMP in rat hepatocytes. Eur J Biochem 117:369–374, 1981
Brass EP, Garrity MJ, Structural specificity for prostaglandin effects on hepatocyte glycogenolysis. Biochem J 267:59–62, 1990
Garrity MJ, Reed MM, Brass EP, Coupling of hepatic prostaglandin receptors to adenylate cyclase through a pertussis toxin sensitive guanine nucleotide regulatory protein. J Pharmacol Exp Ther 248:979–983, 1989
Wasner HK, Regulation of protein kinase and phosphoprotein phosphatase by cyclic AMP and cyclic AMP antagonist. FEBS Lett 57:60–63, 1975
Wasner HK, Biosynthesis of cyclic AMP antagonist in hepatocytes from rats after adrenalin- or insulin-stimulation (isolation, purification and prostaglandin E requirement for its synthesis). FEBS Lett 133:260–264, 1981
Wasner HK, Prostaglandylinositol cyclic phosphate (an antagonist to cyclic AMP). In: Bailey JM (ed) Prostaglandins, leukotrienes and lipoxins. Plenum, New York, pp251–257, 1985
Wasner HK, Salge U, Prostaglandylinositol cyclic phosphate, an antagonist to cyclic AMP. Adv Prostaglandin Thromboxane Leukotriene Res 17:691–695, 1987
Salge U, Untersuchungen zur biologischen Synthese des cyclo AMP-Antagonisten. Thesis, Heinrich-Heine-Universität, Düsseldorf, p 38, 1987
Partke HJ, Wasner HK, Cyclic AMP antagonist, a second messenger for insulin action, inhibits glucose-stimulated insulin secretion in isolated islets of Chinese hamsters. In: Atwater I, Rojas E, Soria D (eds) Biophysics of the pancreatic β-cell. Plenum, New York, pp409–412, 1987
Wasner H, Lemoine H, Junger E, Leßmann M, Kaufmann R, Prostaglandylinositol cyclic phosphate, a new second messenger. In: Bailey JM (ed) Prostaglandins, leukotrienes, lipoxins and PAF. Plenum, New York, pp153–168, 1991
Leßmann M, Zur ‘in vitro’ Biosynthese des cAMP-Antagonisten Prostaglandylinositol-cyclophosphat (cPIP). Thesis, Heinrich-Heine-Universität, Düsseldorf, 1991
Wasner HK, Kaufmann R, Lemoine H, Mass spectrometric identification of prostaglandylinositol, the dephosphorylated cyclic AMP antagonist, cyclic PIP. Analusis 20:171–177, 1992
Wasner HK, Salge U, Gebel M, The endogenous cyclic AMP antagonist, cyclic PIP: its ubiquity, hormone stimulated synthesis and identification as prostaglandylinositol cyclic-phosphate. Acta Diabetol 30:220–232, 1993
Wasner HK, Conrad M, Amini-Hadi-Kiashar H, Mirmohammad-Sadegh A, On the biosynthesis of the endogenous cyclic AMP antagonist, prostaglandylinositol cyclic phosphate (cyclic PIP). Biol Chem Hoppe Seyler 374:733 (abstract IV 50), 1993
Klein HW, Schiltz E, Helmreich EJM, A catalytic role of the dianionic 5′-phosphate of pyridoxal 5′-phosphate in glycogen phosphorylase a. Cold Spring Harbor Conf Cell Prolif 8:305–320, 1981
Yamashita L, Sweat FW, The stimulation of rat liver adenylate cyclase by prostaglandin E1 and E2. Biochem Biophys Res Commun 70:438–444, 1976
Vane JR, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 231:232–235, 1971
Rösen P, Hohl C, Prostaglandins and diabetes. Ann Clin Res 16:300–313, 1984
Lacy PE, Kostianowsky M, Methods for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35–39, 1967
Livesey JH, Hodgkinson SC, Roud HR, Donald RA, Effect of time, temperature and freezing on the stability of immunoreactive LH, FSH, TSH, growth hormone, prolactin and insulin in plasma. Clin Biochem 13:151–155, 1980
Berry MN, Friend DS, High-yield preparation of isolated rat liver parenchymal cells. J Cell Biol 43:506–520, 1969
Pilkis SJ, Claus TH, Johnson RA, Park CR, Hormonal control of cyclic 3′:5′-AMP levels and gluconeogenesis in isolated hepatocytes from fed rats. J Biol Chem 250:6328–6336, 1975
Butcher RW, Ho RJ, Meng HC, Sutherland EW, Adenosine 3′,5′-monophosphate in biological materials. J Biol Chem 240:4515–4523, 1965
Gilman AG, A protein binding assay for adenosine 3′:5′-cyclic monophosphate. Proc Natl Acad Sci USA 67:305–312, 1970
Passonneau JV, Lauderdale VR, A comparison of three methods of glycogen measurement in tissues. Anal Biochem 60:405–412, 1974
Schmidt FH, Die enzymatische Bestimmung von Glucose und Fructose nebeneinander. Klin Wochenschr 39:1244–1247, 1961
Weber TM, Joost HG, Simpson IA, Cushman SW, Methods for assessment of glucose transport activity and number of glucose transporters in isolated rat adipose cells and membrane fractions. In: Kahn CR, Harrison L (eds) Receptor biochemistry and methodology. Insulin receptor, part B: Clinical assessment, biological responses and comparison to the IGF-I receptor. Liss, New York, pp 171–187, 1988
Miller TB, Larner J, Mechanism of control of hepatic glycogenesis by insulin. J Biol Chem 248:3483–3488, 1973
Robison GA, Butcher RW, Sutherland EW, Cyclic AMP. Academic Press, New York, pp 225–226, 1972
Clark MG, Patten GS, Adrenergic regulation of glucose metabolism in rat heart. J Biol Chem 259:15204–15211, 1984
Hucker HB, Zacchei AG, Cox SV, Brodie DA, Cantwell NHR, Studies on the absorption, distribution and excretion of indomethacin in various species. J Pharmacol Exp Ther 153:237–249, 1966
Malchoff CD, Messina JL, Gordon V, Tamura S, Larner J, Inhibition of insulin receptor phosphorylation by indomethacin. Mol Cell Biochem 69:83–90, 1985
Stryer I, Biochemistry. Freeman, New York, p992, 1988
Kuehl FA, Humes JL, Direct evidence for a prostaglandin receptor and its application to prostaglandin measurements. Proc Natl Acad Sci USA 69:480–484, 1972
Mori K, Oka S, Tari A, Ito S, Watanabe Y, E-series prostaglandins activate cAMP mediated potassium currents in follicle-enclosedXenopus oocyte. Biochem Biophys Res Commun 162: 1535–1540, 1989
Murayama T, Nomura Y, Ui M, Enhancement of adenosine A2 and prostaglandin E1 receptor-mediated cAMP generation by prior exposure of Swiss 3T3 fibroblasts to Ca2+-mobilizing receptor agonists or phorbol ester. J Biol Chem 264:15186–15191, 1989
Negishi M, Ito S, Hayaishi O, Prostaglandin E receptors in bovine adrenal medulla are coupled to adenylate cyclase via Gi and to phosphoinositide metabolism in a pertussis toxin-insensitive manner. J Biol Chem 264:3916–3923, 1989
Lee J, Pilch PF, The insulin receptor: structure, function and signaling. Am J Physiol 266:C319-C334, 1994
Exton JH, Some thoughts on the mechanism of action of insulin. Diabetes 40:521–526, 1991
Saltiel AR, Osterman DG, Darnell JC, Chan BL, Sorbara-Cazan LR, The role of glycosylphosphoinositides in signal transduction. Recent Prog Horm Res 45:353–382, 1989
Deeg MA, Brass EP, Rosenberry TL, Inositol glycan phosphate derived from human erythrocyte acetylcholinesterase glycolipid anchor and inositol cyclic 1,2-phosphate antagonize glucagon activation of glycogen phosphorylase. Diabetes 42:1318–1323, 1993
Goueli SA, Ahmed K, Indomethacin and inhibition of protein kinase reactions. Nature 287:171–172, 1980
Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S, Insulin resistance in essential hypertension. N Engl J Med 317:350–357, 1987
Morgan NG, Montague W, Studies on the mechanism of inhibition of glucose-stimulated insulin secretion by noradrenaline in rat islets of Langerhans. Biochem J 226:571–576, 1985
Ratzmann KP, Schulz B, Further support for inhibition of endogenous insulin secretion by exogenous insulin. Exp Clin Endocrinol 85:75–80, 1985
Wasner HK, Preparation of a liver plasma membrane with an adrenaline-responsive adenylyl cyclase after inhibition of prostaglandin synthesis by indomethacin. FEBS Lett 72:127–130, 1976
Pohl SI, Birnbaumer L, Rodbell M, The glucagon-sensitive adenyl cyclase in plasma membranes of rat liver. J Biol Chem 246:1849–1856, 1971
Reeds PJ, Hay SM, Glennie RT, Mackie WS, Garlick PJ, The effect of indomethacin on the stimulation of protein synthesis by insulin in young post-absorptive rats. Biochem J 227:255–261, 1985
Arnstead WM, Leffler CW, Busija DW, Beasley DG, Mirro R, Adrenergic and prostanoid mechanisms in control of cerebral blood flow in hypotensive newborn pigs. Am J Physiol 254: H671-H677, 1988
Chen M, Robertson R, Effects of prostaglandin synthesis inhibitors on human insulin secretion and carbohydrate tolerance. Prostaglandins 18:557–567, 1979
Bratusch-Marrain PR, Vierhapper H, Komjati M, Waldhäusl WK, Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces clearance in health and non-insulin-dependent diabetic man. Diabetologia 28:671–676, 1985
Hitman GA, McCarthy MI, Genetics of non-insulin dependent diabetes mellitus. Baillieres Clin Endocrinol Metab 5:455–476, 1991
Permutt MA, Use of DNA polymorphisms for genetic analysis of non-insulin dependent diabetes mellitus. Baillieres Clin Endocrinol Metab 5:495–526, 1991
Shakir MKM, Reed LH, O'Brian JT, Decreased phospholipase A2 activity in plasma and liver in uncontrolled diabetes mellitus (a defect in the early steps of prostaglandin synthesis?) Diabetes 35:403–410, 1986
Robertson RP, PGE, carbohydrate homeostasis and insulin secretion. Diabetes 32:231–234, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wasner, H.K., Weber, S., Partke, H.J. et al. Indomethacin treatment causes loss of insulin action in rats: involvement of prostaglandins in the mechanisms of insulin action. Acta Diabetol 31, 175–182 (1994). https://doi.org/10.1007/BF00571947
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00571947